Baxalta

Irish drugmaker Shire PLC’s second attempt to buy Baxalta looks more likely to succeed, with Baxalta’s board backing the sweetened offer of $32 billion in cash and stock. If the deal goes through, the combined company would be one of the world’s top 20 drugmakers by revenue and a leader in the sizzling niche of rare disease medicines.